WCLC 2025 - Posters & ePosters-EP.03.01 Identification and Validation of Recurrence-Associated Proteins in Stage I Lung Adenocarcinoma

Pdf Summary

This study aimed to identify proteomic alterations associated with early recurrence in stage I lung adenocarcinoma (LUAD) to better understand tumor biology and improve prediction of recurrence and survival. Twenty stage I LUAD tumor specimens were retrospectively selected from 2016-2022, including 10 cases with early recurrence (within 3 years) and 10 cases with long-term disease-free survival (over 3 years recurrence-free). Tumor epithelial cells were isolated via laser microdissection from paraffin-embedded tissue, and quantitative proteomic analysis was performed using tandem mass tags combined with liquid chromatography-tandem mass spectrometry.<br /><br />Comparing early recurrence versus long disease-free cases, significant differences in protein abundances were identified, with 880 proteins showing differential expression (p<0.05). Among these, 109 recurrence-associated proteins showed a strong correlation (Spearman Rho = 0.796, p<0.0001) with survival-associated proteins identified in a prior proteogenomic study of stage I-III LUAD, suggesting overlap between recurrence and survival-related tumor biology.<br /><br />Patient characteristics such as age, sex, surgery type, and tumor stage/morphology were similar across groups, highlighting proteomic differences as key factors linked to recurrence risk. The findings indicate that specific proteomic signatures in resected stage I LUAD tumors are linked to early recurrence and overall survival outcomes.<br /><br />The authors conclude that proteomic profiling can reveal important biomarkers associated with early tumor relapse in stage I LUAD. They suggest further research to validate these proteomic markers in preoperative biopsy samples to develop clinically useful prognostic tools for individualized patient management.<br /><br />References include recent proteogenomic studies supporting tumor heterogeneity and prognostic proteomic signatures in lung adenocarcinoma. This work was conducted at Inova Fairfax Medical Campus, Virginia. For further information, contact Kei Suzuki (Kei.Suzuki@inova.org).

Asset Subtitle

Kei Suzuki

Meta Tag

Speaker Kei Suzuki

Topic Tumor Biology – Translational Biology

Keywords

stage I lung adenocarcinoma

early recurrence

proteomic alterations

tumor biology

proteomic profiling

tandem mass tags

laser microdissection

differential protein expression

recurrence-associated proteins

prognostic biomarkers